卵泡抑素樣蛋白1(FSTL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Follistatin Like Protein 1 (FSTL1)
FRP; FSL1; Follistatin-related protein 1
- 編號(hào)SEJ085Hu
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍1.56-100ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.59ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 2940 ¥ 4200 ¥ 18900 ¥ 35700 ¥ 294000
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)卵泡抑素樣蛋白1(FSTL1),經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的卵泡抑素樣蛋白1(FSTL1)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 78-93 | 83 |
EDTA plasma(n=5) | 85-104 | 92 |
heparin plasma(n=5) | 79-94 | 82 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的卵泡抑素樣蛋白1(FSTL1),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中卵泡抑素樣蛋白1(FSTL1)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 85-104% | 96-105% | 79-95% | 87-101% |
EDTA plasma(n=5) | 79-96% | 88-95% | 95-103% | 78-92% |
heparin plasma(n=5) | 88-95% | 92-101% | 90-97% | 83-95% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C孵育1小時(shí);
3. 吸棄,加檢測(cè)溶液A100µL,37°C孵育1小時(shí);
4. 洗板3次;
5. 加檢測(cè)溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分鐘;
8. 加終止液50µL,立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將卵泡抑素樣蛋白1(FSTL1)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的卵泡抑素樣蛋白1(FSTL1)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的卵泡抑素樣蛋白1(FSTL1)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的卵泡抑素樣蛋白1(FSTL1)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值),計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPJ085Hu01 | 卵泡抑素樣蛋白1(FSTL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAJ085Hu01 | 卵泡抑素樣蛋白1(FSTL1)多克隆抗體 | WB; IHC; ICC; IP. |
MAJ085Hu27 | 卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | WB; IHC; ICC; IP. |
MAJ085Hu29 | 卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | WB; IHC; ICC; IP. |
MAJ085Hu21 | 卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | WB; IHC; ICC; IP. |
MAJ085Hu22 | 卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | WB; IHC |
MAJ085Hu23 | 卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | WB; IHC; ICC; IP. |
MAJ085Hu24 | 卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | WB; IHC; ICC; IP. |
MAJ085Hu25 | 卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | WB; IHC; ICC; IP. |
FAJ085Hu02 | 抗卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | Flow cytometry. |
FAJ085Hu04 | 抗卵泡抑素樣蛋白1(FSTL1)單克隆抗體 | Flow cytometry. |
SEJ085Hu | 卵泡抑素樣蛋白1(FSTL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
WEJ085Hu | 卵泡抑素樣蛋白1(FSTL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMJ085Hu | 卵泡抑素樣蛋白1(FSTL1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSJ085Hu01 | 卵泡抑素樣蛋白1(FSTL1)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | 自己動(dòng)手制作ELISA試劑盒的主要材料 |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
The Journal of Rheumatology | Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. [PubMed: 22660800] |
Archives of Physiology and Biochemistry | Regulation of follistatin-like protein 1 expression and secretion in primary human skeletal muscle cells [Pubmed: 23419164] |
Journal of Proteomics | Identification of colonic fibroblast secretomes reveals secretory factors regulating colon cancer cell proliferation [Pubmed:25118038] |
PLOS ONE | Growth Differentiation Factor-15 (GDF-15) Levels Are Associated with Cardiac and Renal Injury in Patients Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass [Pubmed:25171167] |
J Mol Med (Berl) | Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance [PubMed: 26199111] |
PLoS One. | Association of Circulating Follistatin-Like 1 Levels with Inflammatory and Oxidative Stress Markers in Healthy Men [pmc:PMC4856269] |
JACC:?Basic?to?Translational?Science | Follistatin like?1?Regulates?Hypertrophy?in?Heart?Failure?with?Preserved?Ejection?Fraction. [pubmed:27430031] |
Sci Rep | Follistatin like-1 aggravates silica-induced mouse lung injury [PMC5428474] |
International Journal of Clinical and Experimental Pathology | Plasma follistatin-like protein 1 is correlated with disease severity in patients with acute pulmonary embolism and predicts short-term mortality [ISSN:1936-2625] |
Endocrine?Journal | High circulating follistatin-like protein 1 as a biomarker of a metabolically unhealthy state [Pubmed: 30745500] |
PLoS One | Associations among circulating levels of follistatin-like 1, clinical parameters, and cardiovascular events in patients undergoing elective percutaneous?… [Pubmed: 31034503] |
British Journal of Cancer | Improved early detection of ovarian cancer using longitudinal multimarker models [Pubmed: 31937926] |
Cell Communication and Signaling | Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice [Pubmed: 32933544] |
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY | Effects of acute endurance exercise on follistatin-like 1 and apelin in the circulation and metabolic organs in rats [Pubmed: 32412800] |
J Cardiol | Prognostic impact of transcardiac gradient of follistatin-like 1 reflecting hemodynamics in patients with dilated cardiomyopathy [34334268] |
Int Heart J | Association between Plasma Follistatin-like Protein 1 Levels and the Presence and Severity of Coronary Artery Disease [34853217] |